z-logo
open-access-imgOpen Access
Case Report on Hirschsprung’s Disease
Author(s) -
Yash Talekar,
Suhas Tivaskar,
Anurag Luharia,
Ravi Christian
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i63b35276
Subject(s) - medicine , vomiting , abdominal pain , leukocytosis , gastroenterology , complete blood count , constipation , surgery
Hirschsprung's disease (HIRSH-SPROONGZ) is a disorder that affects the large intestine (colon) and makes passing faces difficult. As a result of missing nerve cells in the baby's colon muscles, the disease is present at birth (congenital). Hirschsprung’s popularized it in 1886 after “Ruysch” recognized it in 1961. Hirschsprung’s disease is an intrinsic developmental condition. The enteric nervous system has an inherent component. Clinical Findings: Difficulty in passing stool, Abdominal pain, Fever, (Temperature 100-degree f) Vomiting, Failure of thrive, constipation, tiredness. Diagnostic Evaluation: CBC Investigation, blood test, Hb-12.9%, Total RBC count-4.84million/cumm, RDW-13.2%, HCT-36.7%, Total WBC Count-26200 cu mm, Monocytes- 01%, Granulocytes- 30%, Lymphocytes- 65%, Total platelet count-3.5 Lacs/cu mm, ALT(SGPT)-17 U/L, AST (SGOT)-44 U/L. Peripheral Smear: RBCs-Normocytic Normochromic Platelets-Adequate on smear, No Hemiparasite seen, WBCs-Neutrophilic leukocytosis. Therapeutic Intervention: - blood Transfusion, Inj.Aminoven 200 mg BD, Inj. Cefotaxime 400mg BD IV, Inj. Pantaprazole 12mg OD, Syp. Augmentin 3ml BD, Syp. Azee 5ml OD, Inj. Emset 1.8 mg SOS. Outcome: After treatment the child shows improvement his passing stool frequently and relive vomiting, fever, abdominal pain, and facial expression are good. Conclusion: - My patient was admitted in pediatric ward no 22 at AVBRH with a known case of Hirschsprung’s disease, and he had complaint of difficulty in passing stool at birth, after getting appropriate treatment and surgery his condition was improve.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here